Scoop has an Ethical Paywall
Vertex Statement Regarding Trikafta
Vertex is extremely disappointed that Pharmac has decided not to prioritise funding of Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for New Zealand’s cystic fibrosis (CF) patients.
We understand that Pharmac must make choices within a fixed budget, about which patient groups will have access to new, innovative medicines. However, we are surprised by this decision, particularly given their recent public acknowledgment of the clinical impact that Trikafta would have on CF patients in New Zealand.
Vertex remains committed to New Zealand’s CF community and will continue to work collaboratively with Pharmac to find a path forward so that those Kiwis who can benefit from Trikafta have the same access as patients in more than 30 other countries around the world.
Little Miracles Trust: The Little Miracles Trust World Prematurity Day Campaign
NZ Society for the Study of Diabetes: Critical Workforce Shortages Leave People With Type 1 Diabetes Unable To Access Life Changing Technology
Kindergartens Aotearoa: Kindergartens Aotearoa Opposes Lower Standards For Homebased Services
Universities New Zealand - Te Pokai Tara: Three Outstanding Aotearoa New Zealand Students Awarded Rhodes Scholarships
University of Auckland: 800 Mathematicians Set To Converge On Auckland
NZEI Te Riu Roa: NZEI Te Riu Roa Joins Calls To Restore Cut To Pasifika Early Literacy Project